Form 4: Barinthus Biotherapeutics CEO Reports Stock Transaction
Insider Transaction (Form 4)
William Enright, Chief Executive Officer and a Director of Barinthus Biotherapeutics plc., reported multiple transactions in common stock on September 9, 2026.
Summary
- Disposition to the issuer: disposed of 728,454 Ordinary Shares on September 9, 2026 (Indirect).
- Disposition to the issuer: disposed of 514,923 Ordinary Shares on September 9, 2026 (Indirect).
- Disposition to the issuer: disposed of 176,130 Share Option (Right to Buy) on September 9, 2026 (Direct).
- Disposition to the issuer: disposed of 359,605 Share Option (Right to Buy) on September 9, 2026 (Direct).
- Disposition to the issuer: disposed of 440,000 Share Option (Right to Buy) on September 9, 2026 (Direct).
- Disposition to the issuer: disposed of 443,981 Share Option (Right to Buy) on September 9, 2026 (Direct).
- Disposition to the issuer: disposed of 600,000 Share Option (Right to Buy) on September 9, 2026 (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
William Enright — Director, Officer (Chief Executive Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-09 | Disposition to the issuer | Ordinary Shares | 728,454 | — | — | 0 |
| 2026-09-09 | Disposition to the issuer | Ordinary Shares | 514,923 | — | — | 0 |
| 2026-09-09 | Disposition to the issuer | Share Option (Right to Buy) | 176,130 | — | — | 0 |
| 2026-09-09 | Disposition to the issuer | Share Option (Right to Buy) | 359,605 | — | — | 0 |
| 2026-09-09 | Disposition to the issuer | Share Option (Right to Buy) | 440,000 | — | — | 0 |
| 2026-09-09 | Disposition to the issuer | Share Option (Right to Buy) | 443,981 | — | — | 0 |
| 2026-09-09 | Disposition to the issuer | Share Option (Right to Buy) | 600,000 | — | — | 0 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-09 | Disposition to the issuer (728,454 shares) |
| 2026-09-09 | Disposition to the issuer (514,923 shares) |
| 2026-09-09 | Disposition to the issuer (176,130 shares) |
| 2026-09-09 | Disposition to the issuer (359,605 shares) |
| 2026-09-09 | Disposition to the issuer (440,000 shares) |
| 2026-09-09 | Disposition to the issuer (443,981 shares) |
| 2026-09-09 | Disposition to the issuer (600,000 shares) |
Keywords
insider transaction, Form 4, BRNS, Barinthus Biotherapeutics plc., neutral, William Enright
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.